Phase i study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 261-270

  Boku, Narikazu ^a   Muro, Kei ^b   Machida, Nozomu ^c   Hashigaki, Satoshi ^d   Kimura, Nobuyuki ^d   Suzuki, Mie ^d   Lechuga, Mariajose ^e   Miyata, Yoshinori ^f  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d PFIZER INC   (United States)

^e srl   (Italy)

^f Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

Author keywords

Dose finding; Gastric cancer; Phase I; Sunitinib

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; N DEETHYLSUNITINIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HICCUP; HUMAN; JAPANESE; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CISPLATIN; DRUG COMBINATIONS; FEMALE; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; PYRROLES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84896405203     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9948-5     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Inoue M, Tsugane S (2005) Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419-424
3. Ajani JA (2007) Recent developments in cytotoxic therapy for advanced gastric or gastroesophageal carcinoma: the phase III trials. Gastrointest Cancer Res 1:S16-S21
4. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G (2010) Gastric cancer. J Natl Compr Canc Netw 8:378-409
5. Catalano V, Labianca R, Beretta GD, Gatta G, De BF, Van CE (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127-164
6. Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
9. Drescher D, Moehler M, Gockel I, Frerichs K, Muller A, Dunschede F, Borschitz T, Biesterfeld S, Holtmann M, Wehler T, Teufel A, Herzer K, Fischer T, Berger MR, Junginger T, Galle PR, Schimanski CC (2007) Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol 13:3605-3609
10. Zhang H, Wu J, Meng L, Shou CC (2002) Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8:994-998
11. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He-Yao W, Chiba T (1998) Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 43:8-14
12. Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227:365-371
13. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Buchner T, Brandts C, Berdel WE, Serve H (2004) High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 10:1241-1249
14. Wagner AD, Moehler M (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 21:381-385
15. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
16. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
17. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605
18. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A (2010) Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs
19. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021
20. Yoon YK, Im SA, Min A, Kim HP, Hur HS, Lee KH, Han SW, Song SH, Youn OD, Kim TY, Kim WH, Bang YJ (2012) Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cancer Lett 321:128-136
21. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB III, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA (2007) Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 109:33-40
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
23. Gomez-Martin C, Gil-Martin M, Montagut C, Nunez JA, Salazar M, Puig R, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J (2010) A phase I, dose-finding study of sunitinib in combination with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Ann Oncol 21(Supplement 8):818P, abstr
24. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673
25. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
26. Demetri DG, van Oosterom A, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib malate in patients with advanced gastrointestinal stromal tumor following failure of imatinib mesylate due to resistance or intolerance. N Engl J Med submitted
27. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
28. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656
29. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, DePrimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
30. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
31. Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S (2004) Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 34:654-659
32. Yashiro M, Hirakawa K (2010) Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron 3:127-135